Volume 132, Issue 3, Pages 931-937 (March 2007) Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation Edward J. Gane, Peter W. Angus, Simone Strasser, Darrell H.G. Crawford, John Ring, Gary P. Jeffrey, Geoffrey W. McCaughan Gastroenterology Volume 132, Issue 3, Pages 931-937 (March 2007) DOI: 10.1053/j.gastro.2007.01.005 Copyright © 2007 AGA Institute Terms and Conditions
Figure 1 Posttransplantation survival according to the pretransplantation diagnosis of hepatocellular carcinoma. (A) Sixty-two patients listed with hepatocellular carcinoma. (B) Eighty-five patients listed for liver failure without hepatocellular carcinoma (P = .01; log-rank test). Gastroenterology 2007 132, 931-937DOI: (10.1053/j.gastro.2007.01.005) Copyright © 2007 AGA Institute Terms and Conditions
Figure 2 Cumulative proportion of patients with recurrent hepatitis B following liver transplantation for hepatitis B (censored for death). Gastroenterology 2007 132, 931-937DOI: (10.1053/j.gastro.2007.01.005) Copyright © 2007 AGA Institute Terms and Conditions
Figure 3 Plasma (anti-HBs) titers at 1, 3, and 12 months posttransplantation (horizontal bars demonstrate median values). Gastroenterology 2007 132, 931-937DOI: (10.1053/j.gastro.2007.01.005) Copyright © 2007 AGA Institute Terms and Conditions